Emerging therapies in TTP include a sleeping beauty transposon system for the long-term production of functional ADAMTS13 in preclinical mice models [84] and an aptamer to von Willebrand factor to minimize thrombosis [85]. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.